Semaglutide-induced lean mass loss sparks debate: clinical concern or physiological adaptation?

Obesity is a chronic, multifactorial condition defined by a BMI of 30 kg/m2 or greater, linked to insulin resistance, dyslipidemia, hypertension, and increased cardiovascular disease risk. Sarcopenic obesity, characterized by high fat and low lean muscle mass, further exacerbates these risks. Current management includes lifestyle changes, bariatric surgery, and medications like GLP-1 receptor agonists. While semaglutide effectively reduces fat mass, its impact on lean mass requires careful consideration to determine if the loss is clinically significant or merely an adaptation to overall weight reduction.

This 'Dear Editor' letter provides a commentary on the clinical implications of semaglutide-induced lean mass loss, drawing upon existing literature and clinical trial data, specifically referencing the STEP program. The authors discuss the physiological context of weight loss and the importance of distinguishing between clinically significant muscle loss and adaptive changes. The letter aims to frame the ongoing discussion regarding the clinical relevance of body composition changes observed with semaglutide treatment.

This commentary highlights that semaglutide, a GLP-1 receptor agonist administered at 2.4 mg once a week, is an effective fat mass reducer with minimal lean muscle loss, as observed in trials like the STEP program. The authors emphasize that obesity, defined by a BMI of 30 kg/m2 or greater (or 40 kg/m2 for extreme obesity), contributes to over 4 million deaths and 150 million DALYs globally each year. They underscore the importance of understanding if semaglutide's lean mass reduction is a benign physiological adaptation to weight loss or a clinically concerning side effect, particularly in the context of sarcopenic obesity. The letter frames this as a critical factor in determining the overall clinical significance of semaglutide's weight loss benefits, noting that disturbed energy balance, genetic factors, and hormonal influences contribute to obesity's complex etiology.